clinical trials surrogate endpoint surrogate marker measure effect specific treatment may correlate real clinical endpoint necessarily guaranteed relationship national institutes health usa defines surrogate endpoint biomarker intended substitute clinical surrogate markers used primary endpoint undesired eg death number events small thus making impractical conduct clinical trial gather statistically significant number endpoints fda regulatory agencies often accept evidence clinical trials show direct clinical benefit surrogate surrogate endpoints obtained different modalities behavioural cognitive scores biomarkers electroencephalography qeeg mri pet biochemical biomarkers correlate make surrogate common misconception outcome correlate correlated true clinical outcome used valid surrogate endpoint replacement true clinical outcome however proper justification replacement requires effect intervention surrogate endpoint predicts effect clinical outcome much stronger condition context term prentice criteria term surrogate used describing endpoints instead descriptions results interpretations formulated terms designate specific nature category variable surrogate endpoint clinical trial laboratory measurement physical sign used substitute clinically meaningful endpoint measures directly patient feels functions survives changes induced therapy surrogate endpoint expected reflect changes clinically meaningful commonly used example cholesterol elevated cholesterol levels increase likelihood heart disease relationship linear many people normal cholesterol develop heart disease many high cholesterol death heart disease endpoint interest cholesterol surrogate marker clinical trial may show particular drug example simvastatin zocor effective reducing cholesterol without showing directly simvastatin prevents death proof zocors efficacy reducing cardiovascular disease presented five years original introduction secondary another case astrazeneca accused marketing rosuvastatin crestor without providing hard endpoint data relying instead surrogate endpoints company countered rosuvastatin tested larger groups patients drug class effects comparable progression free survival prominent example oncology contexts examples cancer drugs approved basis progressionfree survival failed show subsequent improvements overall survival subsequent studies breast cancer bevacizumab avastin initially gained approval food drug administration subsequently license patient focused surrogate endpoints may offer meaningful alternative overall treatment hivaids medicine counts viral loads used surrogate markers drug approval clinical hepatitis c medicine surrogate endpoint sustained virological response used approval expensive drugs known direct acting antivirals validity surrogate endpoint predicting clinical outcomes several vaccines anthrax hepatitis etc induction detectable antibodies blood used surrogate marker vaccine effectiveness exposure individuals actual pathogen considered recent showed plasma biomarkers potential used surrogate biomarkers alzheimer disease ad clinical trials specifically study demonstrated plasma could potentially used monitor largescale population interventions targeting preclinical ad individuals number instances studies using surrogate markers used show benefit particular treatment later repeat study looking endpoints shown benefit even shown fda came heavy criticism approval alzheimers drug called aduhelm based surrogate endpoint later shown based fraudulent httpsenwikipediaorgwikisurrogateendpoint